Meningococcal disease and vaccination in college students

References

• MacNeil JR, Blain AE, Wang X, Cohn AC. Current epidemiology and trends in meningococcal disease—United States, 1996–2015. Clin Infect Dis. 2017;66(8):1276–81. doi:10.1093/cid/cix993.
   Web of Science ®Google Scholar
• Mbaeyi SA, Joseph SJ, Blain A, Wang X, Hariri S, MacNeil JR. Meningococcal disease among college-aged young adults: 2014-2016. Pediatr. 2019 Jan;143(1). doi:10.1542/peds.2018-2130.
   PubMed Web of Science ®Google Scholar
• Bauman K, Cranney S. School enrollment in the United States: 2018. Current Population Reports: US Census Bureau; September 2020 [accessed 2021 April 28]. www.census.gov/library/publications/2020/demo/P20-584.html .
   Google Scholar
• National Center for Education Statistics. Table 302.60. Percentage of 18- to 24-year-olds enrolled in college, by level of institution and sex and race/ethnicity of student: 1970 through 2019 [accessed 2021 April 22]. https://nces.ed.gov/programs/digest/d20/tables/dt20_302.60.asp?current=yes .
   Google Scholar
• Imrey PB, Jackson LA, Ludwinski PH, England AC III, Fella GA, Fox BC, Isdale LB, Reeves MW, Wenger JD. Meningococcal carriage, alcohol consumption, and campus bar patronage in a serogroup C meningococcal disease outbreak. J Clin Microbiol. 1995;33(12). doi:10.1128/jcm.33.12.3133-3137.1995.
   PubMed Web of Science ®Google Scholar
• Imrey PB, Jackson LA, Ludwinski PH, England AC III, Fox BC, Isdale LB, Reeves MW, Wenger JD. Outbreak of serogroup C meningococcal disease associated with campus bar patronage. Am J Epidemiol. 1996;143(6):624–30. doi:10.1093/oxfordjournals.aje.a008792.
   PubMed Web of Science ®Google Scholar
• Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk factors for meningococcal disease in college students. JAMA. 2001;286(6):688–93. doi:10.1001/jama.286.6.688.
   PubMed Web of Science ®Google Scholar
• Mandal S, Wu HM, MacNeil JR, Machesky K, Garcia J, Plikaytis BD, Quinn K, King L, Schmink SE, Wang X, et al. Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States. Clin Infect Dis. 2013;57(3):344–48. doi:10.1093/cid/cit243.
   PubMed Web of Science ®Google Scholar
• McNamara LA, Thomas JD, MacNeil J, Chang HY, Day M, Fisher E, Martin S, Poissant T, Schmink SE, Steward-Clark E, et al. Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-fHbp in response to a university serogroup B meningococcal disease outbreak—Oregon, 2015–2016. J Infect Dis. 2017;216(9):1130–40. doi:10.1093/infdis/jix446.
   PubMed Web of Science ®Google Scholar
• Breakwell L, Whaley M, Khan UI, Bandy U, Alexander-Scott N, Dupont L, Vanner C, Chang HY, Vuong JT, Martin S, et al. Meningococcal carriage among a university student population – United States, 2015. Vaccine. 2018;36(1):29–35. doi:10.1016/j.vaccine.2017.11.040.
   PubMed Web of Science ®Google Scholar
• Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54:1–21.
   PubMedGoogle Scholar
• Mbaeyi SA, Blain A, Whaley MJ, Wang X, Cohn AC, MacNeil JR. Epidemiology of meningococcal disease outbreaks in the United States, 2009-2013. Clin Infect Dis. 2019;68(4):580–85. doi:10.1093/cid/ciy548.
   PubMed Web of Science ®Google Scholar
• Oliver S. Meningococcal vaccine policies among colleges and universities -United States, 2017. National Immunization Conference; May 16, 2018. Accessed April 28, 2021.
   Google Scholar
• Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2016. Updated 2017; [accessed 2021 July 27]. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report.pdf .
   Google Scholar
• Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report; 2017. Updated 2018. [accessed 2021 July 27]. www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2017.pdf .
   Google Scholar
• Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report; 2018. Updated 2019 [accessed 2021 July 27]. www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2018.pdf .
   Google Scholar
• Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report; 2015. Updated 2017 [accessed 2021 July 27]. www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2015.pdf .
   Google Scholar
• Kumar A, Murray DL, Havlichek DH. Immunizations for the college student: a campus perspective of an outbreak and national and international considerations. Pediatr Clin North Am. 2005;52(1):229–41. doi:10.1016/j.pcl.2004.10.009.
   PubMed Web of Science ®Google Scholar
• Martinón-Torres F. Deciphering the burden of meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59(2):S12–S20. doi:10.1016/j.jadohealth.2016.03.041.
   PubMed Web of Science ®Google Scholar
• Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30:B3–B9. doi:10.1016/j.vaccine.2011.12.062.
   PubMed Web of Science ®Google Scholar
• Mbaeyi SA, Bozio CH, Duffy J, Rubin LG, Hariri S, Stephens DS, MacNeil JR. Meningococcal vaccination: recommendations of the advisory committee on immunization practices, United States, 2020. MMWR Recomm Rep. 2020;69(9):1–41. doi:10.15585/mmwr.rr6909a1.
   PubMed Web of Science ®Google Scholar
• Schaffner W, Baker CJ, Bozof L, Engel J, Offit PA, Turner JC. Addressing the challenges of serogroup B meningococcal disease outbreaks on campuses, infectious diseases in clinical practice.  Bethesda (MD): National Foundation for infectious diseases; 2014 .
   Google Scholar
• Cohn A, MacNeil J, Harrison L, Hatcher C, Theodore J, Schmidt M, Pondo T, Arnold KE, Baumbach J, Bennett N, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184–91. doi:10.1086/649209.
   PubMed Web of Science ®Google Scholar
• Soeters HM, McNamara LA, Blain AE, Whaley M, MacNeil JR, Hariri S, Mbaeyi SA. University-based outbreaks of meningococcal disease caused by serogroup B, United States, 2013–2018. Emerg Infect Dis. 2019;25(3):434–40. doi:10.3201/eid2503.181574.
   PubMed Web of Science ®Google Scholar
• Harrison LH, Pelton SI, Wilder-Smith A, Holst J, Safadi MA, Vazquez JA, Taha MK, LaForce FM, von Gottberg A, Borrow R, et al. The global meningococcal initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine. 2011;29(18):3363–71. doi:10.1016/j.vaccine.2011.02.058.
   PubMedGoogle Scholar
• Parikh SR, Campbell H, Bettinger JA, Harrison LH, Marshall HS, Martinon-Torres F, Safadi MA, Shao Z, Zhu B, von Gottberg A, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483–98. doi:10.1016/j.jinf.2020.05.079.
   PubMed Web of Science ®Google Scholar
• MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of Serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the advisory committee on immunization practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171–76. doi:10.15585/mmwr.mm6441a3.
   PubMed Web of Science ®Google Scholar
• Wu K, Mulholland EK, Edwards KM. Choosing a mass immunization program against meningococcal B. N Engl J Med. 2020;382(4):379–82. doi:10.1056/NEJMclde1916746.
   PubMed Web of Science ®Google Scholar
• Rivero-Calle I, Raguindin PF, Gómez-Rial J, Rodriguez-Tenreiro C, Martinón-Torres F. Meningococcal group B vaccine for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B. Infect Drug Resist. 2019;12:3169.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Meningococcal disease: surveillance data tables; 2019 [accessed 2021 April 28]. https://www.cdc.gov/meningococcal/surveillance/surveillance-data.html
   Google Scholar
• Meyer S. Epidemiology of meningococcal disease among college students - United States, 2014-2016. Advisory Committee on Immunization Practices Meeting. Atlanta (GA): Centers for Disease Control and Prevention; February 22, 2018 [accessed 2021 Apr 28]. https://stacks.cdc.gov/view/cdc/59918 .
   Google Scholar
• Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd protection from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326(7385):365–66. doi:10.1136/bmj.326.7385.365.
   PubMed Web of Science ®Google Scholar
• Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol. 2005;162(1):89–100. doi:10.1093/aje/kwi160.
   PubMed Web of Science ®Google Scholar
• Maiden MC, Ibarz-Pavón AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, Walker AM, Evans MR, Kroll JS, Neal KR, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd protection. J Infect Dis. 2008;197(5):737–43. doi:10.1086/527401.
   PubMed Web of Science ®Google Scholar
• Harrison LH, Stephens DS. Good news and bad news — 4CMenB vaccine for group B Neisseria meningitidis. N Engl J Med. 2020;382(4):376–78. doi:10.1056/NEJMe1916440.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, Dull PM; V59P13 Study Group. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis. 2009;49(1):e1–10. doi:10.1086/599117.
   PubMed Web of Science ®Google Scholar
• Reisinger KS, Baxter R, Block SL, Shah J, Bedell L, Dull PM. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol. 2009;16(12):1810–15. doi:10.1128/CVI.00207-09.
   PubMed Web of Science ®Google Scholar
• Chang LJ, Hedrick J, Christensen S, Pan J, Jordanov E, Dhingra MS. A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine. 2020;38(19):3560–69. doi:10.1016/j.vaccine.2020.03.017.
   PubMed Web of Science ®Google Scholar
• Dhingra MS, Peterson J, Hedrick J, Pan J, Neveu D, Jordanov E. Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study. Vaccine. 2020;38(33):5194–201. doi:10.1016/j.vaccine.2020.06.013.
   PubMed Web of Science ®Google Scholar
• Weston WM, Friedland LR, Wu X, Howe B. Immunogenicity and reactogenicity of co-administered tetanus–diphtheria–acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration. Vaccine. 2010;29(5):1017–22. doi:10.1016/j.vaccine.2010.11.057.
   PubMed Web of Science ®Google Scholar
• Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, Sullivan K, Gilmet G, Reinhardt A. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med. 2005;159(10):907–13. doi:10.1001/archpedi.159.10.907.
   PubMed Web of Science ®Google Scholar
• Baxter R, Reisinger K, Block SL, Percell S, Odrljin T, Dull PM, Smolenov I. Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents. Pediatr Infect Dis J. 2014;33(11):1169–76. doi:10.1097/INF.0000000000000438.
   PubMed Web of Science ®Google Scholar
• Gill CJ, Baxter R, Anemona A, Ciavarro G, Dull P. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents. Hum Vaccin. 2010;6(11):881–87. doi:10.4161/hv.6.11.12849.
   PubMed Web of Science ®Google Scholar
• Robertson CA, Hedrick J, Bassily E, Greenberg DP. Persistence of bactericidal antibodies 4 years after a booster dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D). Vaccine. 2019;37(8):1016–20. doi:10.1016/j.vaccine.2019.01.008.
   PubMed Web of Science ®Google Scholar
• Robertson CA, Greenberg DP, Hedrick J, Pichichero M, Decker Md, Saunders M. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine. Vaccine. 2016;34(44):5273–78. doi:10.1016/j.vaccine.2016.09.003.
   PubMed Web of Science ®Google Scholar
• Tipton M, Daly W, Senders S, Block SL, Lattanzi M, Mzolo T, Barbi S, Pellegrini M, Keshavan P. MenACWY-CRM conjugate vaccine booster dose given 4-6 years after priming: results from a phase IIIb, multicenter, open label study in adolescents and adults. Vaccine. 2019;37(42):6171–79. doi:10.1016/j.vaccine.2019.08.065.
   PubMed Web of Science ®Google Scholar
• Áñez G, Hedrick J, Simon MW, Christensen S, Jeanfreau R, Yau E, Pan J, Jordanov E, Dhingra MS. Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study. Hum Vaccin Immunother. 2020;16(6):1292–98. doi:10.1080/21645515.2020.1733867.
   PubMed Web of Science ®Google Scholar
• Soeters HM, Whaley M, Alexander-Scott N, Kanadanian KV, MacNeil JR, Martin SW, McNamara LA, Sicard K, Vanner C, Vuong J, et al. Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a college—Rhode Island, 2015–2016. Clin Infect Dis. 2017;64(8):1115–22. doi:10.1093/cid/cix091.
   PubMed Web of Science ®Google Scholar
• Østergaard L, Vesikari T, Absalon J, Beeslaar J, Ward BJ, Senders S, Eiden JJ, Jansen KU, Anderson AS, York LJ, et al. A bivalent meningococcal B vaccine in adolescents and young adults. N Engl J Med. 2017;377(24):2349–62. doi:10.1056/NEJMoa1614474.
   PubMed Web of Science ®Google Scholar
• Perrett KP, McVernon J, Richmond PC, Marshall H, Nissen M, August A, Percell S, Toneatto D, Nolan T. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study. Vaccine. 2015;33(39):5217–24. doi:10.1016/j.vaccine.2015.06.103.
   PubMed Web of Science ®Google Scholar
• Nolan T, Santolaya ME, de Looze F, Marshall H, Richmond P, Henein S, Rheault P, Heaton K, Perrett KP, Garfield H, et al. Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine. Vaccine. 2019;37(9):1209–18. doi:10.1016/j.vaccine.2018.12.059.
   PubMed Web of Science ®Google Scholar
• Østergaard L, Vesikari T, Senders SD, Flodmark CE, Kosina P, Jiang HQ, Maguire JD, Absalon J, Jansen KU, Harris SL, et al. Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months. Vaccine. 2021;39(32):4545–54. doi:10.1016/j.vaccine.2021.06.005.
   PubMed Web of Science ®Google Scholar
• Deceuninck G, Lefebvre B, Tsang R, Betala-Belinga JF, De Serres G, De Wals P. Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch. Vaccine. 2019;37(31):4243–45. doi:10.1016/j.vaccine.2019.06.021.
   PubMed Web of Science ®Google Scholar
• Read RC, Dull P, Bai X, Nolan K, Findlow J, Bazaz R, Kleinschmidt A, McCarthy M, Wang H, Toneatto D, et al. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine. Vaccine. 2016;35(3):427–34. doi:10.1016/j.vaccine.2016.11.071.
   PubMed Web of Science ®Google Scholar
• Marshall HS, McMillan M, Koehler AP, Lawrence A, Sullivan TR, MacLennan JM, Maiden MCJ, Ladhani SN, Ramsay ME, Trotter C, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med. 2020;382(4):318–27. doi:10.1056/NEJMoa1900236.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Andrews N, Parikh SR, Campbell H, White J, Edelstein M, Bai X, Lucidarme J, Borrow R, Ramsay ME. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309–17. doi:10.1056/NEJMoa1901229.
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Harvey BM, Pichichero ME, Simon MW, Combs SP, Blatter MM, Marshall GS, Catteau G, Dobbelaere K, Descamps D, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial. Pediatr Infect Dis J. 2011;30(12):e225–34. doi:10.1097/INF.0b013e31822d28df.
   PubMed Web of Science ®Google Scholar
• Arguedas A, Soley C, Loaiza C, Rincon G, Guevara S, Perez A, Porras W, Alvarado O, Aguilar L, Abdelnour A, et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine. 2010;28(18):3171–79. doi:10.1016/j.vaccine.2010.02.045.
   PubMed Web of Science ®Google Scholar
• Velentgas P, Amato AA, Bohn RL, Chan KA, Cochrane T, Funch DP, Dashevsky I, Duddy AL, Gladowski P, Greenberg SA, et al. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf. 2012;21(12):1350–58. doi:10.1002/pds.3321.
   PubMed Web of Science ®Google Scholar
• Myers TR, McNeil MM, Ng CS, Li R, Marquez PL, Moro PL, Omer SB, Cano MV. Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016. Vaccine. 2020;38(40):6291–98. doi:10.1016/j.vaccine.2020.07.039.
   PubMed Web of Science ®Google Scholar
• Tseng HF, Sy LS, Ackerson BK, Hechter RC, Tartof SY, Haag M, Slezak JM, Luo Y, Fischetti CA, Takhar HS, et al. Safety of quadrivalent meningococcal conjugate vaccine in 11- to 21-year-olds. Pediatrics. Jan 2017;139(1). doi:10.1542/peds.2016-2084.
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Lucksinger GH, Absalon J, Beeslaar J, Eiden J, Jansen KU, York LJ, Quinn A, Graversen ME, Perez JL. A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults. Vaccine. 2016;34(12):1465–71. doi:10.1016/j.vaccine.2016.01.044.
   PubMed Web of Science ®Google Scholar
• Muse D, Christensen S, Bhuyan P, Absalon J, Eiden JJ, Jones TR, York LJ, Jansen KU, O'Neill RE, Harris SL, et al. A phase 2, randomized, active-controlled, observer-blinded study to assess the immunogenicity, tolerability and safety of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with tetanus, diphtheria and acellular pertussis vaccine and serogroup A, C, Y and W-135 meningococcal conjugate vaccine in healthy US adolescents. Pediatr Infect Dis J. 2016;35(6):673–82. doi:10.1097/inf.0000000000001124.
   PubMed Web of Science ®Google Scholar
• Senders S, Bhuyan P, Jiang Q, Absalon J, Eiden JJ, Jones TR, York LJ, Jansen KU, O'Neill RE, Harris SL, et al. Immunogenicity, tolerability and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine. Pediatr Infect Dis J. 2016 May;35(5):548–54. doi:10.1097/inf.0000000000001072.
   PubMed Web of Science ®Google Scholar
• Duffy J, Marquez P, Dores GM, Ng C, Su J, Cano M, Perez-Vilar S. Safety surveillance of bivalent meningococcal group B vaccine, vaccine adverse event reporting system, 2014-2018. Open Forum Infect Dis. 2020;7(12):ofaa516. doi:10.1093/ofid/ofaa516.
   PubMed Web of Science ®Google Scholar
• Turner JC, Keller A. College health surveillance network: epidemiology and health care utilization of college students at US 4-year universities. J Am Coll Health. 2015;63(8):530–38. doi:10.1080/07448481.2015.1055567.
   PubMed Web of Science ®Google Scholar
• American College Health Association. Immunization recommendations for college students. [accessed 2021 March 19]. www.acha.org/documents/resources/guidelines/ACHA_Immunization_Recommendations_Oct2018.pdf .
   Google Scholar
• Patton ME, Stephens D, Moore K, MacNeil JR. Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine - advisory committee on immunization practices, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(19):509–13. doi:10.15585/mmwr.mm6619a6.
   PubMed Web of Science ®Google Scholar
• Marshall GS, Tan L. Understanding the category B recommendation for serogroup B meningococcal vaccine. Pediatr. 2017 May;139(5). doi:10.1542/peds.2016-3484.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. ACIP shared clinical decision-making recommendations. [accessed 2020 Dec 15]. www.cdc.gov/vaccines/acip/acip-scdm-faqs.html .
   Google Scholar
• Leeds IL, Namasivayam V, Bamogo A, Sankhla P, Thayer WM. Cost effectiveness of meningococcal serogroup B vaccination in college-aged young adults. Am J Prev Med. 2019;56(2):196–204. doi:10.1016/j.amepre.2018.09.020.
   PubMed Web of Science ®Google Scholar
• Chung GS, Hutton DW. Epidemiological impact and cost-effectiveness of universal meningitis b vaccination among college students prior to college entry. PLoS One. 2020;15(10):e0239926. doi:10.1371/journal.pone.0239926.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Guidance for the evaluation and public health management of suspected outbreaks of meningococcal disease. Version 2.0. September 28, 2019. [accessed 2021 April 28]. https://www.cdc.gov/meningococcal/downloads/meningococcal-outbreak-guidance.pdf.
   Google Scholar
• Elam-Evans LD, Yankey D, Singleton JA, Sterrett N, Markowitz LE, Williams CL, Fredua B, McNamara L, Stokley S. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69(33):1109–16. doi:10.15585/mmwr.mm6933a1.
   PubMed Web of Science ®Google Scholar
• Shaw J, Mader EM, Bennett BE, Vernyi-Kellogg OK, Yang YT, Morley CP. Immunization mandates, vaccination coverage, and exemption rates in the United States. Open Forum Infect Dis. 2018 Jun 2;5(6):ofy130. doi:10.1093/ofid/ofy130.
   PubMed Web of Science ®Google Scholar
• Franco M, Mazzucca S, Padek M, Brownson RC. Going beyond the individual: how state-level characteristics relate to HPV vaccine rates in the United States. BMC Public Health. 2019;19(1):246–246. doi:10.1186/s12889-019-6566-y.
   PubMed Web of Science ®Google Scholar
• Bradford WD, Mandich A. Some state vaccination laws contribute to greater exemption rates and disease outbreaks in the United States. Health Aff (Millwood). 2015;34(8):1383–90. doi:10.1377/hlthaff.2014.1428.
   PubMed Web of Science ®Google Scholar
• Niccolai LM, Yakely AE, Hansen CE. Up-to-date coverage with meningococcal vaccine among adolescents age 17 years: patterns and correlates in the United States, 2017. Vaccine. 2019;37(40):5934–38. doi:10.1016/j.vaccine.2019.08.015.
   PubMed Web of Science ®Google Scholar
• Immunization Action Coalition. State mandates on immunization and vaccine-preventable diseases. February 19, 2020. [accessed 2021 Mar 19]. www.immunize.org/laws/#inf .
   Google Scholar
• National Meningitis Association. NMA advocacy. February 4, 2017. [accessed 2021 Mar 19]. https://nmaus.org/nma-advocacy/.
   Google Scholar
• Haimowitz R, Torres R, Caleb S, Thompson D, Smith A, Ciotoli C, Dannenbaum M, Fu LY. Serogroup B meningococcal vaccination practice patterns on college campuses. Vaccine. 2020. doi:10.1016/j.vaccine.2020.09.035.
   PubMed Web of Science ®Google Scholar
• National Vaccine Advisory Committee (NVAC). Standards for adult immunization practice. May 2, 2016. [accessed 2021 Apr 9]. www.cdc.gov/vaccines/hcp/adults/for-practice/standards/index.html .
   Google Scholar
• Daly KL, Halon PA, Aronowitz T, Ross G. A university health initiative to increase human papillomavirus vaccination rates. J Nurse Pract. 2016;12(6):e281–e286. doi:10.1016/j.nurpra.2016.02.013.
   Google Scholar
• Monn J. An evidence-based project to improve influenza immunization uptake. J Nurse Pract. 2016;12:e159–e162.
   Google Scholar
• Fu LY, Smith A Ciotoli C, Dannenbaum M, Jacobs M. An immunization quality improvement learning collaborative in the college health setting [In press]. J Am Coll Health. doi:10.1080/07448481.2021.1979560.
   Google Scholar
• Caleb S, Thompson D, Haimowitz R, Ciotoli C, Dannenbaum M, Fu LY. How colleges intervene to increase student body vaccination coverage. J Am Coll Health. May 2020:1–8. doi:10.1080/07448481.2020.1752698.
   Web of Science ®Google Scholar
• Abelson J, Dungca N, Kornfield M, Tran A. At college health centers, students battle misdiagnoses and inaccessible care. The Washington Post. July 13, 2020.
   Google Scholar
• American College Health Association. 2010–2011 College health salary and staffing survey report; 2011. Silver Spring (MD):  American College Health Association; 2011.
   Google Scholar
• Oliver SE, Patton ME, Hoban M, Leino V, Mbaeyi SA, Hariri S, MacNeil JR. Evaluation of meningococcal vaccination policies among colleges and universities - United States, 2017. J Am Coll Health. 2019;1–6. doi:10.1080/07448481.2019.1687484.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. COVID-19: considerations for institutions of higher education. December 31, 2020. [accessed 2021 Mar 24]. www.cdc.gov/coronavirus/2019-ncov/community/colleges-universities/considerations.html .
   Google Scholar
• American College Health Association. COVID-19 resources. March 24, 2021. [accessed 2021 Mar 24]. www.acha.org/COVID-19.
   Google Scholar
• American College Health Association. The COVID-19 pandemic’s effect on campus health and well-being services. Report #3, August 4-7, 2020. [accessed  2021 Sep 1]. www.acha.org/documents/Resources/COVID_19/COVID-19_Effect_On_Campus_Health_Services_REPORT_3_August_2020.pdf .
   Google Scholar
• Centers for Disease Control and Prevention. CDC vaccine price list. March 4, 2021. [accessed 2021 Mar 31]. www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html .
   Google Scholar
• Huang L, Goren A, Lee LK, Li VW, Dempsey A, Srivastava A. Disparities in healthcare providers’ interpretations and implementations of ACIP’s meningococcal vaccine recommendations. Hum Vaccin Immunother. 2019:1–12. doi:10.1080/21645515.2019.1682845.
   PubMed Web of Science ®Google Scholar
• Sponsler BA, Egelman G. The impact of the affordable care act on campus healthcare services. July 2013. [accessed 2021 Apr 28]. www.naspa.org/files/dmfile/RPI_Policy_Brief_Affordable_Care_Act_July.13.pdf .
   Google Scholar
• American College Health Association. Standards for student health insurance/benefits coverage. July 2020. [accessed 2021 Apr 28]. www.acha.org/documents/resources/guidelines/ACHA_Standards_SHIBPs_July2020.pdf .
   Google Scholar
• American College Health Association. Update: concerns for colleges promoting students short-term limited duration insurance or other plans that are not compliant with the affordable care act [accessed 2021 Mar 24]. www.acha.org/documents/ACHA_Update_STLDI.pdf .
   Google Scholar
• Affordable Colleges Online. Student guide to health insurance plans. March 24, 2021 [accessed 2021 Apr 28]. www.affordablecollegesonline.org/college-resource-center/student-health-insurance/ .
   Google Scholar
• 111th Congress. Patient protection and affordable care act. Public Law 111-148, March 23, 2010.
   Google Scholar
• Fawole OA, Srivastava T, Fasano C, Feemster KA. Evaluating variability in immunization requirements and policy among U.S. colleges and universities. J Adolesc Health. 2018;63(3):286–92. doi:10.1016/j.jadohealth.2018.06.013.
   PubMed Web of Science ®Google Scholar
• Noesekabel A, Fenick AM. Immunization requirements of the top 200 universities: implications for vaccine-hesitant families. Vaccine. 2017;35(29):3661–65. doi:10.1016/j.vaccine.2017.05.038.
   PubMed Web of Science ®Google Scholar
• Jewett A, Bell T, Cohen NJ, Buckley K, Leino EV, Even S, Beavers S, Brown C, Marano N. US college and university student health screening requirements for tuberculosis and vaccine-preventable diseases, 2012. J Am Coll Health. 2016;64(5):409–15. doi:10.1080/07448481.2015.1117465.
   PubMed Web of Science ®Google Scholar
• Sandler K, Srivastava T, Fawole OA, Fasano C, Feemster KA. Understanding vaccine knowledge, attitudes, and decision-making through college student interviews. J Am Coll Health. 2019:1–8. doi:10.1080/07448481.2019.1583660.
   Web of Science ®Google Scholar
• Ravert RD, Fu LY, Zimet GD. Reasons for low pandemic H1N1 2009 vaccine acceptance within a college sample. Adv Prev Med. 2012:242518. doi:10.1155/2012/242518.
   PubMedGoogle Scholar